Pharma Digests

Forum Replies Created

Viewing 5 posts - 46 through 50 (of 50 total)
  • Author
    Posts
  • in reply to: GCP Guideline #4691
    Pharma Digests
    Pharma Expert

      ICH E6 (R3) Guideline on good clinical practice (GCP)

      in reply to: Lyophilized Product Development #4688
      Pharma Digests
      Pharma Expert

        Critical process parameters for Lyophilized Product Development:
        – Freezing temperature
        – Primary drying temperature
        – Secondary drying temperature
        – Time for annealing
        – Pressure and time

        in reply to: Pharmaceutical Finished Product Analysis #4687
        Pharma Digests
        Pharma Expert

          Fundamental tests for pharmaceutical finished products:
          – Identification
          – Assay
          – Dissolution
          – CU/WV
          – Impurity

          in reply to: FDA GMP Inspection #4683
          Pharma Digests
          Pharma Expert

            Few critical check points for pharmaceutical manufacturing facilities to face FDA GMP audit:
            – SOPs are up-to-date with practice
            – Deviations and CAPAs
            – Previous audit observations
            – Data integrity
            – Cleaning validation

            in reply to: FDA GMP Inspection #4406
            Pharma Digests
            Pharma Expert

              To apply to market a new drug, biologic, or an antibiotic drug for human use (including NDA & ANDA), firstly you need to complete Form 356h.

              Form 356h include: submission date, applicant information, product description, NDA/ANDA application number etc.

              After successful filing your product, FDA will conduct application based GMP inspections to ensure the facility is capable of manufacturing the product consistently and that submitted data are accurate and complete.

            Viewing 5 posts - 46 through 50 (of 50 total)